Adjuvant systemic therapy of breast cancer

• Verfasst von: Schütz, Florian [VerfasserIn]
• Titel: Adjuvant systemic therapy of breast cancer
• Verf.angabe: Florian Schuetz (Department of Gynecology and Obstetrics, Heidelberg University Hospital, Germany)
• E-Jahr: 2011
• Jahr: June 3, 2011
• Umfang: 5 S.
• Fussnoten: Gesehen am 27.10.2022
• Schrift/Sprache: Text englisch, Zusammenfassung deutsch
• Titel Quelle: Enthalten in: Breast care
• Ort Quelle: Basel : Karger, 2006
• Jahr Quelle: 2011
• Band/Heft Quelle: 6(2011), 3, Seite 179-183
• ISSN Quelle: 1661-3805
• DOI: doi:10.1159/000329336
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1820168050

Abstract

The first procedure in primary breast cancer is usually the surgical excision of the tumor. However, a medical therapy is necessary in almost all patients to treat the systemic component of the disease. Which medical approach is recommended depends on the biology of the tumor itself. Endocrine-responsive tumors must be treated by an endocrine therapy according to their menopausal status. In HER2/neu-overexpressing tumors, the monoclonal antibody trastuzumab is part of the standard treatment in combination with chemotherapy. Hormone receptor-negative and non-HER2/neu-overexpressing tumors as well as endocrine-responsive tumors with a high proliferation index or additional risk factors must be treated with chemotherapy as well. This review article gives further information about the available agents and schedules.